Investor Relations
operational analysis:
Traditional MSO Bottlenecks vs. The Novus Solution
CAPITAL & SCALED | DEBT & LIABILITIES | TAXATION & FRICTION | COMPETITIVE MOAT | |
Traditional MSO's | Capital Expenditures: Large sums of capital remain tied up in underperforming real estate holdings, warehouse rental agreements, and cultivating equipment that continues to lose value | The 2026 MSO Debt Wall: Maturing liabilities, hard to refinance in a high-interest climate, risk substantial stock dilution to resolve obligations, urgently needing fresh revenue to bolster Price-to-Book valuations. | Point-of-Sale Consumer Friction: Heavy, localized retail tax layers passed directly onto a fatigued consumer base. | Market Saturation: Oversaturated regional markets experience rapid value erosion as ongoing new dispensary licensing drives cannabis prices below sustainable levels for traditional Balance Sheets and Income Statements. |
Novus Cannabis MedPlan | Liability-Light Scale: Novus self-funded its liability-light model, bypassing cultivation and retail sites to lower overhead and burn rates via insurance receivables. | Balance Sheet Position: High-margin growth engine characterized by a 14.7% increase in EBITDA and a 10.7% rise in cash reserves during Q1 2026, featuring minimal debt and a negligible burn rate. | Schedule III Catalyst: Federal Schedule III status enables cost reductions via tax-advantaged HSA and FSA-deductible PDP plans. This model further encourages recreational users to adopt health plans featuring integrated cannabis benefits. | Zero-Cost Customer Acquisition: Novus lowers MSO acquisition costs through a proprietary agent network and pre-tax, tax-advantaged HSA/FSA plans. This enables MSOs to fully recover point-of-sale discounts via structured reimbursement strategies. |
THE NOVUS SOLUTION (How Novus Assists MSOs) | Guaranteed Retail Traffic: Directs its loyal policyholder network to partner MSO storefronts, introducing a new revenue stream through reimbursement while generating steady customer traffic without increasing operational costs. | Reimbursement Financial Flow: Facilitates efficient, compliant procurement for policyholders and rapid MSO reimbursements and settlements. Medical users generate higher transaction values, converting cash-and-carry customers into a stable, insurance-backed revenue stream. | Market Cash Outlay Novus lowers MSO acquisition costs through a proprietary agent network and pre-tax, tax-advantaged HSA/FSA plans. This enables MSOs to fully recover point-of-sale discounts via structured reimbursement strategies. | Cross-Variable Insights: Equips partner MSOs with deep insights into consumer retention, optimizes inventory forecasting and shelf-space management, and enables the acquisition of higher-value point-of-sale customers alongside strategic brand alignment. |
Q1 2026: Primed for Schedule III Scaling
While competitors pivot, Novus leads with a decade-old, operational carrier infrastructure.
- +14.7% EBITDA: Scaling efficiently via a specialized carrier model.
- +10.7% Cash: Strategic liquidity for the projected $47B market.
- Zero Convertible Debt: No convertible notes; maximizing pure shareholder value.
- Agent Increase 5,000+: Massive distribution reach to millions of prospective policyholders.
- Leak Out: To deliver ironclad float protection, Novus enforces mandatory leak-out provisions for all third-party vendors. This structural guardrail systematically regulates liquidations, eliminating sudden market dumping and ensuring stabilized trading volume.
Capital Structure
As of March 31, 2026
No Toxic Debt Features
| Authorized Shares: | 200 million | |
| Outstanding Shares: | 128,803,624 | |
| Float: | 30,948,730 | |
| Par Value: | $0.001 | |
| Restricted Shares: | 88,989,251 | |
Business EcoSystem
Traditional cannabis is a CapEx trap. Novus’s FinTech gateway scales natively, eliminating agricultural and retail risks.
Asset Driven
Driven by premium receivables, our actuarial strategy yields a 48%–50% quarterly gross margin via a 15,000-agent national sales network.
Valuation Method
The company uses Embedded Value (EV)—an insurance metric that enhances standard book value by combining Net Asset Value (NAV) with the present value of future profits from existing annualized contracts..
Novus Acquisition & Development Corporation (NDEV), operating as Novus Cannabis MedPlan®, has pioneered health insurance that covers both THC/CBD cannabis and traditional prescription drugs since 2015. This proprietary dual-coverage structure provides a financial moat, ensuring stable, recurring revenue for Novus and its in-network providers.
Revenue is generated from insurance premiums, giving policyholders access to medications via an online distribution platform. NDEV has a national reach through 15,000 agents/brokers and over 200 dispensaries.
 | 6/3/2026 | |
| 5/14/2026 | |
| 3/3/2026 | |
| 12/17/2025 | |
| 11/12/2025 | |
| 10/07/2025 | |
| 08/12/2025 | |
| 07/08/2025 | |
| 05/12/2025 | |
| 03/23/2025 |
Cap Structure
As of March 31, 2026
| Authorized Shares: | 200 million | |
| Outstanding Shares: | 128,803,624 | |
| Float: | 30,948,730 | |
| Par Value: | $0.001 | |
| Restricted Shares: | 88,989,251 | |
Due Diligence Links
As of March 31, 2026
| Quote: | Click Here |
| Filings: | Click Here |
| Pitch Deck: | Click Here |
| Investment Highlights Video: | Click Here |
Footnotes:
- Leak Out Vendor Shares: Third-party vendors with treasury-issued stock must sell their shares gradually based on 15% of the average daily trading volume over the past 30 days.
- Insider Sales: No insider selling common stock for three years.
1. Compliance & The “Ancillary” Advantage
Novus is a non-plant-touching technology and administrative platform. Because we do not handle or profit directly from the sale of cannabis, we are not subject to IRS 280E tax restrictions. Our core product is a federally compliant Prescription Drug Program (PDP); cannabis is integrated strictly as a “value-added” discount feature, de-risking the model for institutional investors and traditional banking.
2. Employer-Centric Customization
We empower HR departments to modernize health benefits without legal exposure. Novus provides the framework for companies to align corporate values with modern wellness needs, offering a compliant structure that integrates cannabis-inclusive policies into traditional employer-sponsored health plans.
3. Novus Cannabis RX: Hybrid D2C Platform
Our Direct-to-Consumer platform bridges traditional healthcare and the cannabis industry through a “hybrid” model:
Traditional PDP: A robust prescription drug plan for FDA-approved medications.
Value-Added Access: Exclusive, pre-negotiated discounts at a nationwide network of licensed dispensaries.
Digital Integration: A single, professional portal for both traditional pharmacy benefits and alternative wellness.
4. Strategic Market Expansion
Novus is the primary “on-ramp” for consumers transitioning from the legacy (unregulated) market to legal, lab-tested products. By targeting the untapped employer market and partnering with national insurance brokers, the Novus MedPlan is positioned as the definitive distribution solution for the mainstreaming cannabis economy.
Federal Regulation: A Model Optimized for Growth
Strategic Positioning & Tax Efficiency: Novus is engineered to thrive within the current regulatory landscape. As a non-plant-touching technology and administrative platform, we are structurally insulated from the punitive restrictions that impact cultivators and retailers. This allows Novus to maintain standard corporate tax deductions and a healthy, scalable bottom line.
Institutional-Grade Compliance: We operate as a “grown-up” player in the space, prioritizing rigorous adherence to federal financial standards. Novus maintains strict Anti-Money Laundering (AML) and Bank Secrecy Act (BSA) protocols. This commitment to high-level compliance ensures we remain “institutional-ready,” safeguarding our relationships with traditional banking partners and enterprise-level clients.
Legislative Catalysts as Growth Drivers: Rather than remaining unaffected by federal shifts, Novus is positioned to catch the wave of industry evolution. We view Cannabis Rescheduling (Schedule III) and the SAFER Banking Act as massive growth tailwinds. These milestones will lower the barrier for entry for Fortune 500 employers, triggering a surge in demand for the compliant, turnkey benefit solutions that only Novus provides.
Interstate Scalability: By utilizing a state-regulated insurance framework and a federally compliant Prescription Drug Program (PDP), Novus can scale efficiently across legal jurisdictions. We provide a federally defensible bridge between traditional healthcare and the cannabis industry, offering stability in an evolving market.
Contact Us
* Indicates Required Field
855-228-7355
We are available Monday - Friday 9:00 am - 5:00 pm (EST) Email: info@getnovusnow.com
